Sign in

You're signed outSign in or to get full access.

GT

Gain Therapeutics, Inc. (GANX)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 EPS of $-0.15 beat Wall Street consensus of $-0.165 by $0.015; the beat was driven by streamlined OpEx and research grant/tax credit offsets despite higher Australian taxes and FX drag .
  • Clinical execution advanced: Phase 1b enrollment completed at 21 participants (above the 15 target), ~80% electing extension; initial 90-day data showed MDS-UPDRS Part II/III improvements and consistent PK exposure; no treatment-emergent serious adverse events .
  • Regulatory and development timeline maintained: full 90-day functional and biomarker analysis expected in Q4 2025; IND submission targeted by year-end 2025; extension results expected H2 2026 .
  • Liquidity improved Q/Q to $8.8M cash via July public offering and ATM sales, but going concern risk persists with runway into Q1 2026, necessitating further capital or partnerships .

What Went Well and What Went Wrong

  • What Went Well

    • “We presented early clinical findings ... suggesting GT-02287 has a disease-slowing effect ... stabilization and improvement in MDS-UPDRS scores ... after ~30 days” — Gene Mack, CEO .
    • Phase 1b enrollment completed (21 participants vs. 15 target); ~80% of participants joined or expressed interest in the 9-month extension; Australian authorities approved extension; independent DMC raised no safety concerns .
    • PK exposure in patients fell within projected therapeutic range and matched Phase 1 healthy volunteer exposures; no treatment-emergent serious adverse events reported .

  • What Went Wrong

    • FX and Australian tax headwinds: foreign exchange loss of $0.03M in Q3 and $0.75M YTD; Q3 taxes rose to $0.55M (vs. $0.01M prior-year Q3), pressuring bottom line .
    • Going concern disclosure: current cash expected to fund operations only into Q1 2026; additional capital, cost optimization, or collaborations required .
    • R&D expenses rose $0.2M YoY to $2.85M on Phase 1b costs and FX effects, partially offset by grants/tax credits; G&A ticked up YoY due to stock-based comp and personnel .

Financial Results

MetricQ1 2025Q2 2025Q3 2025
Revenue ($USD)$0.00 $0.00 $0.00
R&D Expense ($USD)$2,257,010 $2,758,973 $2,849,510
G&A Expense ($USD)$2,112,366 $2,330,553 $1,936,267
Total Operating Expenses ($USD)$4,369,376 $5,089,526 $4,785,777
Net Loss ($USD)$4,530,058 $5,809,087 $5,284,373
Diluted EPS ($USD)$-0.16 $-0.19 $-0.15
Cash & Equivalents ($USD)$9,070,102 $6,694,136 $8,807,353
MarginsQ1 2025Q2 2025Q3 2025
Net Income Margin %N/A (no revenue) N/A (no revenue) N/A (no revenue)
EBIT Margin %N/A (no revenue) N/A (no revenue) N/A (no revenue)

Segment breakdown: Gain operates a single segment focused on research and development in pharmaceuticals .

KPIs (Clinical/Operational)

KPIQ1 2025Q2 2025Q3 2025
Phase 1b Enrollment (participants)Initiated; target 15–20 16 enrolled; cap ≤20 21 enrolled; target surpassed
90-day dosing completionPlanning 4Q25 Ongoing 16 completed; 5 to complete in Dec 2025
Study extension participationN/ASought approval to extend ~80% joined/confirmed interest; approved
Safety (TESAEs)N/AN/ANone observed; DMC ok to continue
MDS-UPDRS (Parts II/III)N/AN/ASeveral participants improved at Day 90
PK exposure consistencyN/AN/AWithin therapeutic range; consistent across sampled pts

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
90-day functional & biomarker analysis (Phase 1b)Q4 2025Expected Q4 2025 Expected Q4 2025 Maintained
IND submission (GT-02287 for PD)2025 YEBy year-end 2025 By year-end 2025 Maintained
Phase 1b extension resultsH2 2026Not specifiedExpected H2 2026 New
Dosing duration extension approval (Australia)2025Request submitted; update forthcoming Approved; 12-month total dosing allowed Raised
Phase 1b enrollment2025Cap ≤20 Completed at 21 (above 15 target) Raised
Cash runwayThrough Phase 1b completion (implied) Into Q1 2026; going concern risk Updated; risk disclosed

Earnings Call Themes & Trends

No Q3 2025 earnings call transcript was available in the document set; analysis reflects themes from Q1–Q3 8-K press releases and Q3 10-Q.

TopicPrevious Mentions (Q-2 and Q-1)Current Period (Q3 2025)Trend
Clinical efficacy signals (MDS-UPDRS)Planning first biomarker analysis mid-2025 ; enrollment progress Reported initial 90-day improvements in Parts II/III; disease-slowing suggestion Improving evidence
Safety/TolerabilityPhase 1 in HVs safe; target engagement >50% GCase No TESAE; DMC continuation; transient enzyme elevations normalized Consistently favorable
PK/ExposurePhase 1 exposures in therapeutic range Patient PK consistent, within therapeutic range Consistent
Regulatory path (IND)Targeting IND YE 2025 IND YE 2025 maintained On track
Study operationsEnrollment earlier-than-anticipated; request for dosing extension Enrollment completed; extension approved; ~80% participation Accelerated execution
Financing/liquidity$7.1M public offering (July) ; ATM in place Cash $8.8M; ATM activity; going concern risk Mixed; still capital dependent
FX/tax headwindsNot highlightedFX loss and higher Australian taxes hit results Deteriorating external headwinds
Platform (Magellan™)Emphasized for discovery Continues as core engine Steady focus

Management Commentary

  • “We are encouraged by the progress ... excited to better understand the impact GT-02287 has on the biology of Parkinson’s disease ... disease-slowing effect ... stabilization and improvement in MDS-UPDRS scores ... after approximately 30 days” — Gene Mack, CEO .
  • “We are deeply grateful to the patients ... interest underscores the significant unmet need ... we hope to shift the treatment paradigm and deliver a life-changing treatment” — Gene Mack .
  • “Reaching target enrollment ... analysis ... 4Q 2025 ... extend dosing duration ... valuable feedback for Phase 2 planning” — Gene Mack .

Q&A Highlights

No Q3 2025 earnings call transcript was available in the catalog; no Q&A disclosures to extract. Management held an October 14 KOL event on biomarkers/endpoints; a live Q&A followed, but no transcript was provided in the documents reviewed .

Estimates Context

MetricQ1 2025Q2 2025Q3 2025
EPS Consensus Mean ($)-0.1667*-0.1667*-0.165*
EPS Actual ($)-0.16 -0.19 -0.15
Revenue Consensus Mean ($)0.00*0.00*0.00*
Revenue Actual ($)0.00 0.00 0.00
  • Q3: EPS beat by $0.015; Q2: EPS miss by $0.0233; Q1: EPS beat by ~$0.0067. With no revenue expected/recognized, estimate comparisons are focused on EPS.
    Values marked * were retrieved from S&P Global.

Key Takeaways for Investors

  • Near-term catalyst: full 90-day functional and biomarker analysis in Q4 2025; positive signal continuity (UPDRS improvements, favorable safety/PK) could drive sentiment and re-rate probability of success .
  • IND submission targeted by year-end 2025; an on-time IND is a key gating item for Phase 2 initiation and potential U.S. site expansion .
  • Strong patient engagement (~80% entering extension) and enrollment outperformance (21 vs. 15 target) indicate clinical interest and trial feasibility, de-risking operational execution .
  • Balance sheet supported by July public offering and ongoing ATM, but going concern risk remains; expect continued financing activity (equity, partnerships, grants) to extend runway beyond Q1 2026 .
  • EPS variance vs. consensus is primarily a function of operating expense cadence, FX, and taxes rather than revenue; short-term trading likely reactive to clinical readouts and financing developments .
  • FX/tax headwinds and macro volatility can pressure quarterly EPS even with disciplined OpEx; grants/tax incentives mitigate R&D spend but are non-recurring and program-specific .
  • Medium-term thesis hinges on Phase 2 design quality, biomarker validation, and potential differentiation of GT-02287’s allosteric mechanism; the Magellan™ platform may support pipeline optionality for follow-on indications .